Medical Advocates

HCV Infection/Disease

 
Drugs

General Reports
HCV Protease Inhibitors

Amantadine
Cyclosporine
Etanercept
Erythropoietin
Corticosteroids

Gammaglobulin
Immunoglobulin
Interferons
Ledipasvir
Lopinavir
Meloxicam


Mericitabine
Metformin
Nevirapine

NS5A Inhibitors.
Peg Interferon-Alfa-2a 
Peg Interferon-Alfa-2b  
Raltegravir
Ribavirin

Rifampin
Rituximab
Sofosbuvir
Statins

Steroid Therapy
Tacrolimus
Thalidomide
Valproic Acid
Alternative Therapies
Investigational Therapies
Post-Transplant Drugs



 

HCV Main Page Main New/Newsworthy    Home Page    

Last Update:  April 15, 2014
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R, Halfon P, Marcellin P, Asselah T.
Liver Int
. 2014 Feb;34 Suppl 1:69-78.
Abstract

Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries
Hill A, Khoo S, Fortunak J, et al

Clin Infect Dis. 2014 Jan 6.
Abstract

FULL-TEXT ARTICLE
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
Zhu Y, Chen S.
World J Gastroenterol. 2013 Dec 21;19(47):8963-8973.
Paper

Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients.
Younossi ZM, Singer ME, Mir HM,  et al
J Hepatol
. 2013 Nov 19.
Abstract

Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.
Zhou H, Luo H, Xiao S,  et al
Eur J Clin Microbiol Infect Dis. 2013 Nov 6.
Abstract

Interferon-Free Regimens for Hepatitis C: Combine and Conquer.
Martel-Laferričre V, Bichoupan K, Dieterich DT.
BioDrugs
. 2013 Oct 30
.
Abstract

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C virus.
Maasoumy B, Port K, Calle Serrano B, et al
Aliment Pharmacol Ther. 2013 Oct 16
Abstract

Novel Therapeutic Approaches for Hepatitis C.
Au JS, Pockros PJ.
Clin Pharmacol Ther. 2013 Oct 14.
Abstract


Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
v
an der Meer AJ, Wedemeyer H, Feld JJ,  et al
J Hepatol
. 2013 Aug 20.
Abstract

Drug-drug interactions during antiviral therapy for chronic hepatitis C.
Kiser JJ, Burton JR Jr, Everson GT
Nat Rev Gastroenterol Hepatol. 2013 Jul 2.
Abstract

Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naďve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration.
Chan K, Lai MN, Groessl EJ,  et al
Clin Gastroenterol Hepatol
. 2013 May 22.
Abstract

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Bruce RD, Moody DE, Altice FL,  et al
Expert Rev Clin Pharmacol
. 2013 May;6(3):249-69.
Abstract

Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD, et al
Gastroenterology
. 2013 Mar 4.
Abstract

Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther. 2012;17(6 Pt B):1147-62.
Abstract

Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther
. 2012;17(6 Pt B):1201-10.
Abstract

Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther
. 2012;17(6 Pt B):1183-8.
Abstract

HCV Variants with Decreased Sensitivity to Direct Acting Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan JC, Zhang EZ, et al 
J Virol
. 2012 Nov 14.
Abstract

The changing face of hepatitis C in the new era of direct-acting antivirals.
Soriano V, Labarga P, Fernández-Montero JV,  et al
Antiviral Res
. 2012 Nov 9.
Abstract

FULL-TEXT PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012 Oct;35(4):387-97.

Abstract

Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E, Barreiro P, Soriano V.
Expert Opin Drug Metab Toxicol. 2012 Oct 25.
Abstract

New hepatitis C virus drug discovery strategies and model systems.
Hussain S, Barretto N, Uprichard SL.

Expert Opin Drug Discov
. 2012 Sep;7(9):849-59.
Abstract

Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS, Aspinall E, Liew D, et al
Br J Clin Pharmacol. 2012 Aug 13.
Abstract

New antiviral therapies in the management of HCV infection.
Farnik H, Zeuzem S.

Antivir Ther
. 2012 May 25. 
Abstract

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS 4th, Fried MW
Gastroenterology. 2012 May;142(6):1314-1323.
Abstract

FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep. 2012;4:5..
Paper

Antiviral Drugs and the Treatment of Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep. 2012 Feb 22
Abstract

Antiviral strategies in hepatitis C virus infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol. 2012;56 Suppl:S88-S100
Abstract

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl 1:88-102. .
Abstract

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C.
Liver Int. 2012 Feb;32 Suppl 1:79-87.
.
Abstract

New targets for antiviral therapy of chronic hepatitis C.
Bühler S, Bartenschlager R.
Liver Int. 2012 Feb;32 Suppl 1:9-16.
Abstract

FULL-TEXT ARTICLE
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver. 2011 Dec;5(4):406-17
Paper

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C
in HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG, et al
Clin Infect Dis. 2011 Dec 14
Abstract

Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1025-36.
Abstract

Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol
. 2011 Sep 9.
Abstract

Oral combination therapy: Future hepatitis C virus treatment?
Hézode C.
J Hepatol. 2011 May
Abstract

Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,  et al
J Pharm Pharmacol. 2011 Jul;63(7):883-92.
Abstract

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Masarone M, Persico M.
Expert Rev Anti Infect Ther. 2011 May;9(5):535-43..
Abstract

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
Pearlman BL, Traub N.
Clin Infect Dis. 2011 Apr;52(7):889-900
Abstract

Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
Immunopharmacol Immunotoxicol. 2011 Feb 14
Abstract

Hepatitis C virus Resistance to Protease Inhibitors.
Halfon P, Locarnini S.
J Hepatol
. 2011 Jan 29.
Abstract

Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med
. 2010 Nov 22.
Abstract

Susceptibility of Treatment-Naive HCV Clinical Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X, et al
Antimicrob Agents Chemother
. 2010 Sep 20
Abstract

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,
 et  al
Psychosomatics
. 2010 Sep;51(5):401-8.
Abstract

Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
Cooper C.
Can J Gastroenterol. 2010 Jun;24(6):385-90
Abstract

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob Chemother
. 2010 Mar 23
Abstract

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Singal AK, Singh A, Jaganmohan  et al 
Clin Gastroenterol Hepatol. 2009 Oct 29
Abstract

Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials
Qin XK, Han M, Liu JP.
Zhong Xi Yi Jie He Xue Bao. 2009 Oct;7(10):913-28.
Abstract

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Sroczynski G, Esteban E, Conrads-Frank A,, et a;
J Viral Hepat
. 2009 Jul 28.
Abstract

New and experimental therapies for HCV.
Pereira AA, Jacobson IM.
Nat Rev Gastroenterol Hepatol
. 2009 Jul;6(7):403-11.
Abstract

Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C.
Dove LM, Rosen RC, Ramcharran D, et al
Gastroenterology
. 2009 Jun 12.
Abstract

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
Thompson AJ, McHutchison JG.
 J Viral Hepat. 2009 Jun;16(6):377-87
Abstract

New drug targets for hepatitis C and other flaviviridae viruses.
Paula T, Pablo R, Eugenia V, et al
Infect Disord Drug Targets. 2009 Mar;9(2)
Abstract
 

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy.
Gaudieri S, Rauch A, Pfafferott K, et al
Hepatology
. 2008 Dec 8

Abstract
 
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Gurusamy KS, Osmani B, Xirouchakis E, et al
Cochrane Database Syst Rev
. 2009 Jan 21;(1):CD006803.
Abstract
 
New data and recommendations of antiviral therapy of chronic hepatitis B and C.
Niederau C.
Internist (Berl). 2008 Mar 15
Abstract
 
Treatment regimens for patients with chronic hepatitis C.
Trapero-Marugan M, González-Moreno L, Chaparro-Sánchez M, et al
Minerva Gastroenterol Dietol.
2008 Jun;54(2):209-17.
Abstract
 
Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders:
an international, multicenter cohort study.

Posthouwer D, Yee TT, Makris M, et al
J Thromb Haemost. 2007 Aug;5(8):1624-1629.
Abstract
 
Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in
Chronic Hepatitis C.

Lecube A, Hernández C, Simó R, et al
Am J Gastroenterol. 2007 Jul 7;
Abstract
 
Viral determinants of resistance to treatment in patients with hepatitis C
Wohnsland A, Hofmann WP, Sarrazin C.   
Clin Microbiol Rev.
2007 Jan;20(1):23-38.
Abstract
 
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
Mehta SH, Lucas GM, Mirel LB, et al
AIDS.
2006 Nov 28;20(18):2361-9.
Abstract
 
Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term follow-up study.
Saadoun D, Resche-Rigon M, et al 
Arthritis Rheum.
2006 Oct 30;54(11):3696-3706
Abstract
 
Antiviral treatment of hepatitis C.
Toniutto P, Fabris C, Pirisi M.
Expert Opin Pharmacother.
2006 Oct;7(15):2025-35.
Abstract
 
Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis C Treated by Private Practice Gastroenterologists.
Hofmann WP, Bock H, Weber C, et al
Z Gastroenterol. 2006 Jan;44(1):25-31.
Abstract

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based
approach.
Camma C, Di Bona D, Craxi A. 
Curr Pharm Des. 2004;10(17):2123-30.
Abstract
 

    Conference Reports, Abstracts, and Posters
 
 

The effect of nucleoside free HAART on the treatment of chronic HCV infection
M. Vogel, G. Ahlenstiel, G. Klausen, et al
(5IAS Conference)
Abstract


Corticosteroids
 

     Journal Papers, Abstracts, and Commentaries

  Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis C-autoimmune hepatitis overlap syndrome.
Petersen-Benz C, Kasper HU, Dries V, Goeser T.
Clin Gastroenterol Hepatol. 2004 May;2(5):440-3
Abstract

Cyclosporine
 

   Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis.
Hilgard P, Kahraman A, Lehmann N, et al 
World J Gastroenterol. 2006 Feb 7;12(5):697-702.

Paper

Erythropoietin
 

     Journal Papers, Abstracts, and Commentaries
 
 

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Sherman M, Cohen L, Cooper MA, et al 
Can J Gastroenterol.
2006 Jul;20(7):479-85.

Abstract

Epoetin alfa for the Treatment of Combination Therapy-Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus.
Rivkin AM, Chawla S. 
Pharmacotherapy. 2005 Jun;25(6):862-7
Abstract 

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Durante Mangoni E, Marrone A, Saviano D
Antivir Ther. 2003 Feb;8(1):57-63
Abstract

Etanercept
 

     Journal Papers, Abstracts, and Commentaries

  Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F.

Autoimmun Rev. 2008 Dec;8(2):104-6.

Abstract

Gammaglobulin
 

     Journal Papers, Abstracts, and Commentaries
 
  Fibrosis regression induced by intravenous gammaglobulin treatment.
Amital H, Rewald E, Levy Y, et al.
Ann Rheum Dis
2003 Feb;62(2):175-177

Abstract

Immunoglobulin
 

      Journal Papers, Abstracts, and Commentaries
 
  Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin: Clinical and Economic Appraisal.
Piazza M, Sagliocca L, Tosone G, et al
BioDrugs. 1999 Oct;12(4):291-300.
Abstract

Ledipasvir
 

      Journal Papers, Abstracts, and Commentaries
 
  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.
Abstract

Lopinavir
 

    Conference Reports, Abstracts, and Posters
 
  POSTER
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment:
final results of a randomised, proof-of- principle clinical trial (KAMON 2 Study)

H. Hasson, L. Galli, G. Gallotta
(6th IAS Conference)

Poster      Abstract

Meloxicam
 

     Journal Papers, Abstracts, and Commentaries
 
  Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C.
Kagawa T, Shiozawa H, Kojima SI, et al 
Hepatol Res.
2007 Sep 6;

Abstract
 
Mericitabine
 

      Journal Papers, Abstracts, and Commentaries
 
  In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Metformin
 

     Journal Papers, Abstracts, and Commentaries
 
  Treatment of insulin resistance with metformin in naďve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, et al 
Hepatology. 2009 Dec;50(6):1702-8.
Abstract

Nevirapine
 

     Journal Papers, Abstracts, and Commentaries
 
  Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens : CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
Torti C, Costarelli S, De Silvestri A, et al 
Drug Saf.
2007;30(12):1161-9.

Abstract

NS5A Inhibitors.
 

     Journal Papers, Abstracts, and Commentaries

  FULL-TEXT ARTICLE
Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F,  et al
Infect Drug Resist
. 2014 Mar 5;7:41-56.
Paper

Raltegravir
 

     Journal Papers, Abstracts, and Commentaries
 
 

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother
. 2009 Dec 23

Abstract


Rifampin
 

Rifampin/Pyrazinamide

     Journal Papers, Abstracts, and Commentaries

  Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D, Warman A, Beckon A,  et al.
Clin Infect Dis. 2003 Jun 15;36(12):E158-61

Abstract

Rituximab
 

   Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.
Bonilla-Abadía F, Echeverri AF,  et al
Case Report Rheumatol. 2012;2012:923897.
Paper

FULL-TEXT ARTICLE
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.
Stamataki Z, Tilakaratne S, Adams DH, McKeating JA.

PLoS One
. 2011;6(9):e25789.
Paper

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients.
Terrier B, Saadoun D, Sčne D, et al
Arthritis Rheum
. 2009 Jul 30;60(8):2531-2540.
Abstract

Hepatitis C virus infection and rituximab therapy after renal transplantation.
Fabrizi F, Martin P, Elli A, et al 
Int J Artif Organs.
2007 May;30(5):445-9.

Abstract


Sofosbuvir
 

      News Releases
 
  U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Gilead
Dec. 6, 2013
News

      Journal Papers, Abstracts, and Commentaries
 

 
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM, Stepanova M, Nader F,  et al
Hepatology. 2014 Apr 8.
Abstract

FULL-TEXT PDF ARTICLE
[MUST BE DOWNLOADED DIRECTLY FROM SITE)

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
Gaetano JN.
Drug Healthc Patient Saf. 2014 Mar 31;
Paper

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals.
Hagan LM, Sulkowski MS, Schinazi RF.
Hepatology
. 2014 Mar 28.
Abstract

Hepatitis C virus: Here comes all-oral treatment.
Dugum M, O'Shea R.
Cleve Clin J Med
. 2014 Mar;81(3):159-72.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors
Mericitabine and Sofosbuvir.

Tong X, Le Pogam S, Li L, et al
J Infect Dis. 2014 Mar;209(5):668-75.

Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Koff RS.
Aliment Pharmacol Ther
. 2014 Mar;39(5):478-87
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Guedj J, Pang PS, Denning J, Rodriguez-Torres M,  et al
Antivir Ther
. 2014 Jan 24.

Abstract

Sofosbuvir for the treatment of hepatitis C virus.
Asselah T.
Expert Opin Pharmacother
. 2014 Jan;15
Abstract

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
Koff RS.
Aliment Pharmacol Ther
. 2014 Jan 6.

Abstract

IFNL4-ΔG Genotype is Associated with Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated with Sofosbuvir and Ribavirin.
Meissner EG, Bon D, Prokunina-Olsson L,  et al
J Infect Dis. 2013 Dec 23.
Abstract

FULL-TEXT ARTICLE

Sofosbuvir has come out of the magic box.
Alavian SM.
Hepat Mon. 201316;13(12):e16916.
Paper


Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics.
Ferguson MC.
Evid Based Med
. 2013 Dec 12.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effects of Sofosbuvir-based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C.
Younossi ZM, Stepanova M, Henry L,  et al
Clin Gastroenterol Hepatol
. 2013 Dec 5.
Abstract

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection.
Gane EJ, Stedman CA, Hyland RH, et al
Gastroenterology
. 2013 Nov 18.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.

Abstract

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F,  et al
Hepatology
. 2013 Sep;58(3):902-11
Abstract

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Osinusi A, Meissner EG, Lee YJ,  et al
JAMA. 2013 Aug 28;310(8):804-11
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE

Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Zeng QL, Zhang JY, Zhang Z, et al
World J Gastroenterol
. 2013 Jun 7;19(21):3199-206
Paper

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M, et al
Am J Transplant
. 2013 Jun;13(6
Abstract

Sofosbuvir-Based Antiviral Therapy for Treatment Naďve Hepatitis C Genotypes 1, 2, and 3.
Sharma P.
Gastroenterology
. 2013 May 27.
Abstract

FULL-TEXT ARTICLE
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C, Sun JH, O'Boyle DR 2nd, et aL
Antimicrob Agents Chemother. 2013 May;57(5):2054-65
Paper

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection:
a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T,  et al
Lancet Infect Dis
. 2013 May;13(5):401-8.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M,  et al
N Engl J Med. 2013 Apr 23.
Abstract

FULL-TEXT ARTICLE
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Apr;22(4):527-36.
Abstract
 

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
Jacobson IM, Gordon SC, Kowdley KV,  et al
N Engl J Med. 2013 Apr 23.
Abstract

A WEEK--IN- REVIEW FEATURED REPORT
Sofosbuvir , a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Mar 1.

Abstract

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised,
multicentre phase 2 trial.
Kowdley KV, Lawitz E, Crespo I,  et al
Lancet. 2013 Mar 14
Abstract

   
 

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Gane EJ, Stedman CA, Hyland RH,
N Engl J Med
. 2013 Jan 3;368(1):34-44.
Abstract

  Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naďve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M, Lawitz E,  et a;
J Hepatol. 2012 Nov 23.

Abstract
   
 

FULL-TEXT ARTICLE
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
Lam AM, Espiritu C, Bansal S, Micolochick S
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68
Paper

 

Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Chun BK, Du J, Zhang HR,
Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):886-96
Abstract

 

Statins
 

   Journal Papers, Abstracts, and Commentaries
 
  Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B, Neyts J, Delang L.
Antiviral Res
. 2014 Mar 5.
.
Abstract

Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci
. 2009 Sep 3.
Abstract


Steroid Therapy
 

 Journal Papers, Abstracts, and Commentaries
 
  Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?
Romero Gutiérrez M, Del Campo Terrón S,  et al
J Med Virol
. 2014 May;86(5):758-64.

Abstract
   
Thalidomide
 

   Journal Papers, Abstracts, and Commentaries
 
  Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
Milazzo L, Biasin M, Gatti N, et l
Am J Gastroenterol. 2006 Feb;101(2):399-402

Abstract

Valproic Acid
 

     Journal Papers, Abstracts, and Commentaries
 
  The safety of valproic Acid use for patients with hepatitis C infection.
Felker BL, Sloan KL, Dominitz JA, Barnes RF.
Am J Psychiatry
2003 Jan;160(1):174-8

Abstract

Alternate Therapies
 

     Journal Papers, Abstracts, and Commentaries

 
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M, Schlosser B, Fülöp B, et al

J Viral Hepat
. 2012 Aug;19(8):547-53
Abstract

High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure
Estes JD, Stolpman D, Olyaei A 

Arch Surg.
2003 Aug;138(8):852-8.
Abstract

The use of alternative medicine in the treatment of hepatitis C.
Bean P
Am Clin Lab 2002 May;21(4):19-21
Abstract

 

HCV Main Page Main New/Newsworthy    Home Page    

HCV Drugs

.